The clinical significance of T-cell regulation in hypertension treatment

作者：Miaoxin Fu, Ming Lv, Jinyue Guo, Aihua Mei, Hang Qian, Handong Yang, Wenwen Wu, Zhixin Liu, Jixin Zhong, Ying Wei, Xinwen Min, Haiyan Wu, Jun Chen · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1550206 · 被引用次数：7 · 研究领域：Sodium Intake and Health、Atherosclerosis and Cardiovascular Diseases、Hormonal Regulation and Hypertension

Hypertension, a globally prevalent condition, is closely associated with T cell-mediated inflammatory responses. Studies have shown that T cells, by secreting pro-inflammatory cytokines such as interferon-gamma (IFN-γ), Interleukin-17 (IL-17), and Tumor necrosis factor-alpha (TNF-α), directly lead to vascular dysfunction and elevated blood pressure. The activation of Th1 and Th17 cell subsets, along with the dysfunction of regulatory T cells (Tregs), is a critical mechanism in the onset and progression of hypertension. This review explores the role of T cells in the pathophysiology of hypertension and discusses potential therapeutic strategies targeting T cell regulation, such as immunotherapy and gene-editing technologies. These emerging treatments hold promise for providing personalized therapeutic options for hypertensive patients, reducing inflammatory complications, and improving treatment outcomes.